Stock Market Update - February 17, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. OLB - The OLB Group, Inc.
Price: $1.48 | Change: +256.54% ($1.0649)
OLB experienced a remarkable surge, rocketing over 256% around February 2026. This significant jump was primarily driven by the announcement of a global partnership agreement between The OLB Group, a fintech and payment technology provider, and PayPal.
Under this strategic collaboration, OLB will integrate popular PayPal payment solutions—including PayPal Checkout, Venmo, PayPal Pay Later, and PayPal Credit—directly into its SecurePay payment gateway. This aims to simplify the checkout process for merchants, offer unified reporting, and leverage PayPal's strong fraud protection.
What makes this particularly interesting is the potential for OLB's merchants to access cross-border acceptance in over 200 markets. This expanded reach, coupled with a next-generation checkout experience, is expected to drive higher conversion rates and payment volumes, which OLB's CEO referred to as a "force multiplier."
2. AMPGZ - Amplitech Group, Inc. Series B Right
Price: $0.3 | Change: +71.43% ($0.125)
AMPGZ saw a notable rise of 71.43% around mid-February 2026. This surge in AmpliTech Group, Inc. Series B Rights followed its new listing on the Nasdaq Capital Market in early February. The move to Nasdaq significantly boosted the visibility and accessibility of these Series B Rights to a much broader investor base.
Adding to the positive sentiment, AmpliTech Group reported impressive unaudited full-year revenue of approximately $25 million for fiscal year 2025, marking a substantial 163% increase from the previous year. The company is also looking ahead, projecting at least $50 million in revenue for fiscal year 2026, suggesting another year of strong growth and anticipated profitability.
These promising financial results, coupled with the increased market exposure from the Nasdaq listing, appear to be key factors in why investors have been paying close attention to AMPGZ. The company recently raised over $18 million to help fund manufacturing and research, underpinning its future expansion plans.
3. SGN - Signing Day Sports, Inc.
Price: $0.4199 | Change: +67.69% ($0.1695)
SGN recently experienced an impressive 67.69% gain, fueled by significant progress in its proposed business combination with BlockchAIn Digital Infrastructure, Inc. and its affiliate, One Blockchain LLC. The major catalyst was the U.S. SEC declaring the merger's registration statement (Form S-4) effective, a crucial regulatory milestone that clears the path toward finalizing the transaction.
Following this regulatory green light, Signing Day Sports announced a special meeting for its stockholders on March 13, 2026, where they will vote on approving the business combination. Definitive proxy materials detailing the merger are expected to be distributed around February 18, 2026, ahead of the anticipated completion in February or March 2026.
Upon the deal's close, Signing Day Sports will become part of the new combined entity, BlockchAIn Inc., which is expected to trade on the NYSE American under the ticker "AIB." This new company is positioned as a U.S.-based digital infrastructure platform focused on artificial intelligence (AI) and high-performance computing (HPC), projecting substantial revenue and net income for 2024.
4. PLYX - Polaryx Therapeutics, Inc. Common Stock
Price: $3.96 | Change: +64.32% ($1.55)
PLYX soared 64.32% recently after Polaryx Therapeutics announced a key development for their SOTERIA Phase 2 trial. The clinical-stage biotechnology company selected a Contract Research Organization (CRO) – essentially, a partner firm that helps run clinical studies – to manage this important trial.
This news was a significant catalyst because it marks a crucial step towards getting the SOTERIA trial underway. The trial aims to test PLX-200, Polaryx's lead drug candidate, across four different rare pediatric lysosomal storage disorders. The company had previously received FDA clearance for this trial and is preparing to start it in the first half of 2026.
For a biotech company focused on developing new medicines, moving from planning to active trial preparation is a major milestone. Investors often react strongly to concrete progress in the long and complex drug development process, especially when targeting unmet needs in rare diseases.
5. BDMD - Baird Medical Investment Holdings Limited
Price: $1.26 | Change: +63.64% ($0.49)
BDMD just saw an impressive 63.64% gain, following a series of strategic announcements that highlight the company's aggressive expansion in key markets. A major driver was the recent commercial deployment of its minimally invasive Microwave Ablation (MWA) technology at Bakersfield Memorial Hospital in California. This marked a significant milestone, bringing advanced care for benign thyroid tumors to the vital San Joaquin Valley region and solidifying Baird Medical's U.S. presence.
The company also underscored its global ambitions with premier clinical education programs across the United States and Japan. These initiatives, including advanced training at Columbia University and a high-profile workshop in Yokohama, aim to accelerate the adoption of thyroid ablation technology worldwide.
What makes this particularly interesting is how these efforts tie into their broader strategy, which also includes a new partnership with Stonewood Key Capital to leverage the Hainan Free Trade Port for enhanced global operations and supply chain efficiency. These combined moves in market expansion, education, and strategic partnerships appear to be fueling investor confidence.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.